PMID

Data

Article Title

Organization

Synthesis of dihydroimidazole tethered imidazolinethiones and their activity as novel antagonists of the nuclear retinoic acid receptor-related orphan receptors (RORs).

Torrey Pines Institute For Molecular Studies

SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious ROR¿ Inhibitor.

Central Pharmaceutical Research Institute

Discovery of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent ROR¿t inverse agonists.

Fudan University

Discovery of novel pyrazole-containing benzamides as potent ROR¿ inverse agonists.

Biogen

Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-¿ (ROR¿ or RORc).

Genentech

Discovery of Tertiary Amine and Indole Derivatives as Potent ROR?t Inverse Agonists.

Glaxosmithkline

Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent ROR¿t inhibitors.

Glaxosmithkline

Discovery of tert-amine-based ROR?t agonists.

Fudan University

AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2.

Astrazeneca

Discovery of novel N-sulfonamide-tetrahydroisoquinolines as potent retinoic acid receptor-related orphan receptor ?t agonists.

Fudan University

Tricyclic-Carbocyclic ROR?t Inverse Agonists-Discovery of BMS-986313.

Bristol Myers Squibb

Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor ?t inverse agonists for the treatment of autoimmune diseases.

Fudan University

Tricyclic sulfones as potent, selective and efficacious ROR?t inverse agonists - Exploring C6 and C8 SAR using late-stage functionalization.

Bristol Myers Squibb

Substituted diaryl ether compounds as retinoic acid-related orphan Receptor-?t (ROR?t) agonists.

Bristol Myers Squibb

Novel Tricyclic Pyroglutamide Derivatives as Potent ROR?t Inverse Agonists Identified using a Virtual Screening Approach.

Bristol Myers Squibb

Substituted benzyloxytricyclic compounds as retinoic acid-related orphan receptor gamma t (ROR?t) agonists.

Bristol Myers Squibb

Discovery and optimization of new oxadiazole substituted thiazole ROR?t inverse agonists through a bioisosteric amide replacement approach.

Phenex Pharmaceuticals

Discovery of BMS-986251: A Clinically Viable, Potent, and Selective ROR?t Inverse Agonist.

Bristol Myers Squibb

Discovery and pharmacological evaluation of indole derivatives as potent and selective ROR?t inverse agonist for multiple autoimmune conditions.

Advinus Therapeutics

Discovery of N-indanyl benzamides as potent ROR?t inverse agonists.

Fudan University

Rationally Designed, Conformationally Constrained Inverse Agonists of ROR?t-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy.

Bristol-Myers Squibb

Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2.

Astrazeneca

Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist.

Karo Pharma

Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (ROR?t) inhibitor, S18-000003.

Shionogi

From ROR?t Agonist to Two Types of ROR?t Inverse Agonists.

Fudan University

Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor.

Seattle Veterans Affairs Medical Center

Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer.

University of Texas Southwestern Medical Center